Kari Hagen

TOP PMR SPECIALIST DR. AASTIK BHATT JOINS HCAH

3 min read

TOP PMR SPECIALIST DR. AASTIK BHATT JOINS HCAH

HCAH, India’s leading full-stack rehab and geriatric platform today announced a significant development by welcoming Dr Aastik...

Read More

1 IN 6 INDIVIDUALS STRUGGLE WITH INFERTILITY

2 min read

1 IN 6 INDIVIDUALS STRUGGLE WITH INFERTILITY

Mother’s Day celebrates the invaluable role of mothers worldwide. While many women embrace motherhood, infertility makes it...

Read More

SMBXL elevates the digital experience for MSMEs by introducing India’s largest B2B and B2C Online Hospital and Medical Supplies Expo

3 min read

SMBXL elevates the digital experience for MSMEs by introducing India’s largest B2B and B2C Online Hospital and Medical Supplies Expo

SMBXL, a leading technology company that supports MSMEs, has launched India’s largest ONLINE B2B and B2C Hospital...

Read More

Philips extends leadership in virtually helium-free MRI with more than 1,000 systems installed, expanding patient access worldwide

3 min read

Philips extends leadership in virtually helium-free MRI with more than 1,000 systems installed, expanding patient access worldwide

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a significant milestone as...

Read More

Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

2 min read

Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

Coherus BioSciences, Inc. (Coherus, NASDAQ: CHRS) today announced the launch of UDENYCA ONBODY™, the company’s on-body injector (OBI)...

Read More

AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer

2 min read

AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the first subject has been dosed at...

Read More

Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA  

2 min read

Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA  

Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administration (FDA) has approved...

Read More

New Vision-Training Software Improves Low Vision

2 min read

New Vision-Training Software Improves Low Vision

Marking the Low Vision awareness month of February, RevitalVision announced the expansion of their team in India...

Read More

Brii Biosciences Announces Agreement to Acquire VBI’s IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies

2 min read

Brii Biosciences Announces Agreement to Acquire VBI’s IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies

Brii Biosciences Limited (“Brii Bio,” “we,” or the “Company”, stock code: 2137.HK), a biotechnology company developing therapies to...

Read More

Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical Trial

2 min read

Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical Trial

 Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer,...

Read More